PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Pelthos Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$20.26+0.11 (+0.55%)
Close on Oct 19, 2026
- Market cap
- $71.71M
- P/E (TTM)
- –
- Dividend yield
- –
Pelthos Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Market Cap | $77.56M | $166.30M |
| Enterprise Value | $53.37M | $88.19M |
| PS Ratio | 1.79 | 3.65 |
Enterprise value
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 1.23 | 2.51 |
Income (trailing twelve months)
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Revenue | $43.30M | $58.34M |
| Gross Profit | $34.03M | $105.94M |
| Operating Income | -$57.78M | -$21.40M |
| Pretax Income | -$93.78M | -$14.34M |
| Net Income | -$86.39M | -$22.46M |
| EBITDA | -$57.78M | -$16.91M |
| EPS (Diluted) | -$26.30 | -$0.83 |
Margins
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 78.6% | 52.9% |
| Operating Margin | -133.4% | -44.0% |
| Pretax Margin | -216.6% | -13.3% |
| Profit Margin | -199.5% | -40.2% |
| EBITDA Margin | -133.4% | -30.2% |
Returns
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -125.0% | -40.9% |
| Return on Capital Employed (ROCE) | -54.8% | -38.1% |
Balance sheet
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $24.19M | $61.43M |
| Net Cash (Debt) | $24.19M | $15.35M |
| Net Cash Per Share | $6.32 | $0.66 |
| Equity (Book Value) | -$1.50M | $49.09M |
| Book Value Per Share | -$0.39 | $1.37 |
| Tangible Book Value | -$63.58M | $23.52M |
| Working Capital | $31.40M | $76.81M |
Financial position
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.98 | 3.34 |
| Quick Ratio | 1.21 | 2.44 |
| Interest Coverage | -7.81 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$42.30M | -$12.35M |
Efficiency
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.63 | 0.39 |
| Inventory Turnover | 0.43 | 2.70 |
| Revenue Per Employee | $470.70K | $404.87K |
| Profits Per Employee | -$939.04K | -$703.34K |
| Employee Count | 92 | 74 |
Dividends and yields
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -111.4% | -23.3% |
Shares
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 3,828,470 | 58,127,000 |
| Shares Change (YoY) | 434.9% | 10.9% |
| Shares Change (QoQ) | 10.3% | 0.54% |
| Shares Held by Institutions | 35.6% | 59.4% |
Taxes
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$7.39M | $79.87K |
Scores
| Measure | Pelthos Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -1.62 | -0.22 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Pelthos Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.